Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, China.
Biochem Biophys Res Commun. 2011 Mar 18;406(3):311-4. doi: 10.1016/j.bbrc.2011.02.042. Epub 2011 Feb 15.
Malignant glioma is the most common primary brain tumor. Malignant melanoma is the most malignant of skin tumor. The two malignancies are poorly responsive to conventional treatment regimens such as chemotherapy. Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma. Resistance to alkylating agents such as TMZ correlates with increased expression of DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Several studies in animal models have demonstrated that decreasing MGMT level with gene therapy could overcome TMZ resistance and enhance tumor cell death. In the present review, we provide an overview of recent advances in this field.
恶性胶质瘤是最常见的原发性脑肿瘤。恶性黑色素瘤是最恶性的皮肤肿瘤。这两种恶性肿瘤对化疗等常规治疗方案反应不佳。替莫唑胺（TMZ）是一种用于治疗神经胶质瘤、星形细胞瘤和黑色素瘤的 DNA 烷化剂。对 TMZ 等烷化剂的耐药性与 DNA 修复蛋白 O6-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）的表达增加有关。动物模型中的几项研究表明，通过基因治疗降低 MGMT 水平可以克服 TMZ 耐药性并增强肿瘤细胞死亡。在本综述中，我们提供了该领域最新进展的概述。
